Abstract: The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVA?E3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.

Abstract: The present invention pertains to compositions and methods of making high concentration protein formulations of a therapeutic protein.

Abstract: Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Abstract: A liposomal system for delivery of an active agent comprising: lipid component forming a liposome; destabilizing agent associated with the lipid component, the destabilizing agent capable of forming reactive oxygen species to oxidise unsaturated lipids and destabilise liposomal membrane; and an active agent; wherein the active agent is releasable from the liposome by exposure to high energy electromagnetic radiation.

Abstract: The instant disclosure provides a long acting IL-15 receptor agonist, related compositions and methods of preparation and use, for example, in the treatment of conditions responsive to therapy effective to provide, for example, sustained immune activation and/or anti-tumor activity.

Abstract: Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.

Abstract: The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

Abstract: The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and/or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.

Abstract: This invention provides nanoparticles containing protein-polynucleotide complexes and methods of manufacture and methods of their use. These particles, when administered to a subject in need, are capable of delivering these complexes to target cells and target intracellular locations where they can perform a therapeutic function. In some embodiments, this therapeutic function includes gene editing, induction of gene skipping, and regulation of gene expression. The instant nanoparticles are generally formed by designing and synthesizing the polynucleotide to according to its intended function, combining it with a protein selected for its substrate specificity and enzymatic function in a manner to form a polynucleotide-protein complex, encapsulating the complexes by dispersion into a water-insoluble surfactant system, optionally adding a targeting ligand, and stabilizing the nanoparticles by crystallization of the ligand to the surface of the nanoparticles.

Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.

Abstract: The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.

Abstract: The present invention relates to a pharmaceutical composition comprising a radiohybrid agent containing a silicon-fluoride and a chelating group wherein either the fluorine is 18F or the chelating group contains a chelated radioactive metal, wherein the composition has a pH of 4.0-6.0 and further comprises: 0.1-200 mM citrate buffer; 1-100 mg/mL ethanol; and 5-10 mg/mL sodium chloride.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

Abstract: A method for preparing a complex comprising a radioisotope of gallium for use in radiotherapy or in a medical imaging procedure, said method comprising adding a gallium radioisotope solution obtained directly from a gallium radionuclide generator to a composition comprising a pharmaceutically acceptable buffer and optionally also a pharmaceutically acceptable basic reagent, in amounts sufficient to increase the pH to a level in the range of 3 to 8, wherein the composition further comprises a chelator that is able to chelate radioactive gallium within said pH range and at moderate temperature, said chelator being optionally linked to a biological targeting agent. Kits and compositions for use in the method are also described and claimed.

Abstract: A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I.

Abstract: Moist wipes having improved dispersibility are provided. The moist wipes are sufficiently strong during use and disperse sufficiently quickly under real world conditions to be flushable without creating potential problems for sanitation systems.

Abstract: A method of reducing the appearance of hyperpigmented skin is disclosed. The method can include topically applying to hyperpigmented skin a composition comprising an aqueous and/or glycerin extract of Rhododendron ferrugineum leaf to reduce melanocyte pigmentation in the skin.

Abstract: A deep-sea water concentrate skin application kit of deep-sea active concentrate and skincare formula is provided. The deep-sea water concentrate skin application kit has the following properties of micronizing the skincare formulas immediately, and decreasing the surface tension of the deep-sea active concentrate immediately; furthermore, the deep-sea active concentrate can become a driving force for the permeability of the micronized skincare formulas. Therefore, the deep-sea water concentrate skin application kit can be more easily absorbed into the skin (dermis). A manufacturing method of the deep-sea water concentrate skin application kit is also provided to improve skin appearance.

Abstract: A method for reducing the appearance of post-acne marks, lightening dark spots and discoloration, fading post-acne marks faster and/or preventing appearance of new post-acne marks by applying a skin care composition. The skin care composition contains a vitamin B3 compound, hydroxycinnamic acid, and water at a pH of less than 5.0.

Abstract: The present disclosure relates to compositions for altering the tone or color of the hair, the compositions comprising at least one amino acid, at least one carboxylic acid, monoethanolamine, and at least one hair coloring agent comprising a direct dye. The disclosure also relates to methods of using the compositions.

Abstract: A method for managing skin tone comprising reducing the synthesis of melanin by applying a skin treatment composition to skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

Abstract: An anhydrous deodorant stick that contains from 0.1% to 10% a substituted or unsubstituted 2-pyridinol-N-oxide material, an antimicrobial having a microbial inhibition concentration of at most about 2500 ppm, and one or more structural elements. The one or more structural elements can include waxes, natural oils, liquid triglycerides, or mixtures thereof.

Abstract: Cellular energy levels in skin cells affected by oxidative stress can be improved through the use of a skin care composition that includes a sucrose ester and a fatty alcohol present at a specific ratio. The fatty alcohol and sucrose ester, when incorporated into a skin care composition at a specific ratio, can provide a synergistic improvement in cellular ATP level for skin cells suffering from the effects of oxidative stress.

Abstract: A multi-action skin-lightening cosmetic composition is provided. The cosmetic composition comprises ascorbic acid delivered in a stable form in a high concentration and, optionally, other complementary active ingredients.

Abstract: The salt-stable cosmetic composition is in the form of a low viscosity emulsion (oil in water) and is especially stable at high electrolyte contents and includes a salt-stable polymeric system comprising a polymer blend such that the salt-stable cosmetic composition resists phase separation, pilling and gellifying at high salt content, conferring a flowable, lightweight lotion-type texture.

Abstract: A method of treating keratinous substrates, includes actuating a packaged makeup priming product that includes a mousse-forming composition to release a makeup priming composition. The method further includes applying the makeup priming composition to the keratinous substrate to form a primed keratinous substrate; and applying a makeup topcoat composition comprising colorant over the primed keratinous substrate. The mousse-forming composition comprises propellant gas; water; and a water-soluble or water-dispersible polymer. The mousse-forming composition has a Surface Tension Value of less than about 63 mN/m and is substantially free of surfactant. Kits are also provided.

Abstract: This cosmetic product has extensibility and imparts use feels such as silkiness and smoothness, and further demonstrates excellent soft focus effects, and contains: (A) spherical organopolysiloxane particles of which 90% by mole or more are constituted from organosilsesquioxane units and which have a volume average particle size of 0.1 to 30 ?m and an average refractive index of 1.44 to 1.57, and; (B) an oil agent; and one or more selected from (C) a silicone crosslinked product and (D) a silicon resin coating silicon rubber powder.

Abstract: A gelled composition includes at least 50% by weight of at least one hydrocarbon oil that includes a content by weight of isoparaffins ranging from 90 to 100%, a content by weight of normal paraffins ranging from 0 to 10% and a content of carbon of biological origin greater than or equal to 90% relative to the total weight of the hydrocarbon oil, and at least 1% by weight of at least one gelling agent chosen from among: polymers chosen from homopolymers and copolymers obtained from at least one monomer chosen from among isoprene, butadiene, styrene and (meth)acrylates, and the mixtures of same, and non-polymer gelling agents, relative to the total weight of the gelled composition.

Abstract: A transparent liquid composition that does not substantially contain ethyl alcohol, contains water as the main solvent, and has a high concentration of perfume is provided. The transparent liquid composition comprises: (a) 3-20% by mass of a perfume component; (b) a hydrogenated castor oil to which 30-60 moles of polyoxyethylene is added; (c) an alkanol obtained by addition polymerization of 20-30 moles of polyoxyprolylene and 20-30 moles of polyoxyethylene; (d) one type or more of a surfactant having an Inorganic-value/Organic-value of 0.70-1.20; and (e) 40% by mass or greater of an aqueous component other than ethyl alcohol, wherein the blending ratio (d/(b+c)) of the component (d) to the sum of the blending amounts of the components (b) and (c) is 0.03-0.60, and ethyl alcohol is not substantially contained.

Abstract: Disclosed are certified natural skin compositions and related methods of use. Certified natural compositions include diaper rash compositions, antioxidant sunscreen compositions, with or without natural sparkle or shimmer ingredient(s), and after-sun, tan-enhancing bronzer, skin toner or moisturizer composition with natural sparkle or shimmer. The inventive natural skin compositions are specifically formulated with natural ingredients, such that the products are suitable for certification as “natural” and/or “organic” products, and more particularly formulated with a variety of high-quality ingredients that care for and protect skin.

Abstract: Provided are compositions that stimulate the oxytocin receptor in the skin of a subject thereby leading to improved skin appearance and youthfulness. Also provided are processes of rejuvenating the skin of a subject to improve a youthful appearance by application of one or more compositions as provided herein.

Abstract: One aspect of the present invention provides an anti-obesity agent, an anti-dementia agent, a deodorant, an anti-aging agent, an anti-glycation agent, an anti-type I allergy agent, a hypotensive agent, a flavor improving agent, a muscle enhancing agent, and a bone metabolism improving agent which contain a bagasse decomposition extract as an active ingredient.

Abstract: The present invention relates to non-aqueous topical compositions comprising a halogenated salicylanilide and the use of such compositions in the topical treatment or prevention of diseases and infections, particularly conditions caused by Gram-positive bacteria, for example the topical treatment or prevention of skin infections such as acne, atopic dermatitis and impetigo. Also disclosed are methods for preparing the gel composition.

Abstract: A pourable, non-toxic lubricating composition containing lambda carrageenan as an antiviral agent, for protection from viruses, including but not limited to sexually-transmitted viruses and respiratory viruses, and methods of using the lubricating compositions as a non-oily, pseudoplastic lubrication product and administering the carrageenan for reducing the propagation of sexually-transmitted viruses, including HPV, during sexual activity.

Abstract: Compositions and methods are provided for lamellar and defect reconstruction of corneal stromal tissue using biomaterials that form a defined gel structure in situ. Such gels can serve as cellular or acellular lamellar substitutes to reconstruct corneal stroma, facilitate matrix remodeling, and support multilayered re-epithelialization of wounded corneal stromal tissue, as well delivery vehicles for cells, biomolecules, and/or pharmaceutical agents to wound sites throughout the body.

Abstract: Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.

Abstract: Oral pharmaceutical compositions containing rifamycin SV, or a pharmaceutically salt thereof, characterized in that they are formulated in a higher strength (about 600 mg/tablet) and in such a manner to obtain a modified profile of the rifamycin SV, or a pharmaceutically acceptable salt thereof, in the proximal portion of the intestine, i.e. in the small intestine (duodenum, jejunum and ileum). In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of small intestine bacterial overgrowth (SIBO) and/or irritable bowel syndrome (IBS) and/or in the treatment of cholera. In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of hepatic encephalopathy, hepatic cirrhosis, pouchitis and/or spontaneous bacterial perotinitis.

Abstract: Ready to use liquid formulations of diclofenac potassium are disclosed which are particularly well suited for packaging in stick-packs.

Abstract: The present invention relates to a self-emulsionable mineral oil used as a vehicle in poultry vaccines, and a method for producing self-emulsionable mineral oil, comprising the steps of: placing paraffinic mineral oils in a container with stirring; shake until a homogeneous mixture is obtained; without suspending stirring, add adjuvants on the homogeneous mixture; and continue stirring until a homogeneous mixture is obtained.

Abstract: Described herein are therapeutic pH responsive compositions useful for the treatment of cancer. The compositions involve combining a STING activating polymer micelle, such as PC7A, with a non-peptide STING agonist, such as cGAMP. Methods of administering these compositions in the treatment of cancer are also disclosed. These methods include administration of the pharmaceutical compositions by intratumoral injection in the treatment of solid tumors.

Abstract: A method for continuously processing at least two liquid feed streams is provided. A system for continuously processing at least two liquid feed streams is also provided.

Abstract: A PN composition for treating multiple organ dysfunction syndrome (MODS) comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and/or liposomes organized as a lipid bilayer and/or other particle configurations. This is a PN composition that takes up nitric oxide and releases it with enhanced rapidity enabling it to shift the balance of nitric oxide from one that exacerbates organ damage and decreased survivability to one that reverses and/or inhibits organ damage and increases survivability.

Abstract: Multiparticulate compositions including an active agent and a gelling agent are disclosed. The multiparticulate compositions are prepared by an aqueous-based spray and congeal process.

Abstract: Novel microsphere compositions for use in parenteral formulations are provided. The microspheres comprise a biodegradable polymer of a molecular weight greater than 10,000 daltons, an active therapeutic agent, and a cellulose-derived material such as ethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, or sodium carboxymethyl cellulose. The microsphere compositions decreased deviation in mean microsphere diameter, improved drug entrapment, and improved microsphere stability.

Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject).

Abstract: A purified exosome product includes spherical or spheroid exosomes with a diameter no greater than 250 nm. In some embodiments, the purified exosome product has a moisture content of no more than 10%. The purified exosome product can be reconstituted to prepare an artificial blood product.

Abstract: The present disclosure describes a method of encapsulating cells in a crosslinked alginate microbead using a microfluidic encapsulation device.

Abstract: Described herein is a composition for delivery of an active agent. The composition includes a peptide coacervate, wherein the peptide coacervate includes one or more peptides derived from histidine-rich proteins, and an active agent encapsulated in the peptide coacervate. Further provided are a method for encapsulation of an active agent in a peptide coacervate, a method for delivery of an active agent, and a method for treating or diagnosing a condition or disease in a subject in need thereof.

Abstract: Compositions, processes, and methods are provided including, but not limited to, a composition including a plurality of clay nanoparticles, wherein each clay nanoparticle comprises an anionic component and a cationic component wherein the anionic component has the formula (I): [(Si8MgbLic)O20(OH)4]??(I) wherein 5.5<b?6, and wherein c>0 and b/c>12.